Matthew Ku, MBBS, PhD, FRACP, RACP, FRCPA/RCPA, on CAR T-Cell Therapy JNJ-90014496's Safety Profile in R/R LBCL
The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.
This video originally appeared on our sister site, OncLive®.
"Overall, only 7 patients, or 28% of the recommended phase 2 dose group, reported a serious treatment emergent adverse event."
Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in a phase 1b clinical trial (NCT05421663). At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, data from this trial were presented.
CGTLive®'s sister site, OncLive®, interviewed Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital, about the findings during the conference. Ku went over the highlights of the safety and efficacy results presented.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
